Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Abstract

BACKGROUND Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma relapse after initial therapy. Bendamustine plus rituximab is often used in the relapsed or refractory setting. We assessed the efficacy and safety of adding ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in… (More)
DOI: 10.1016/S1470-2045(15)00465-9

Topics

8 Figures and Tables

Cite this paper

@article{ChananKhan2016IbrutinibCW, title={Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.}, author={Asher Alban Chanan-Khan and Paula Cr{\'a}mer and Fatih Demirkan and Graeme Fraser and Rodrigo Santucci Silva and Sebastian Grosicki and Aleksander Pristupa and A Cecile Jw Janssens and Jiř{\'i} Mayer and Nancy L. Bartlett and Marie-Sarah Dilhuydy and Halyna Pylypenko and Javier Loscertales and Abraham Avigdor and Simon A J Rule and Diego Villa and Olga S Samoilova and Panagiots Panagiotidis and Andre Goy and A. Silva Mato and Miguel Arturo Pavlovsky and Claes Karlsson and Michelle B Mahler and Mariya Salman and Steven C. Sun and Charles D. Phelps and Sriram Balasubramanian and Angela Howes and Michael J Hallek}, journal={The Lancet. Oncology}, year={2016}, volume={17 2}, pages={200-211} }